A while back on the compass thread we were introduced to 177Lu PSMA for metastatic prostate cancer. The results that have been produced so far are impressive. Radioligand approaches have been tried for some time, though they never seemed that effective.

A group has now extended this approach to colorectal cancer. It is expected that this could be used to target any cancer type by switching the antigen target.

http://jnm.snmjournals.org/content/58/11/1735  

This appears to be a substantial step forward. Specific targeting removes toxicity and leads to impressive response rates. With the recent research, 100% of the mice attained a complete response.